BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication – GenomeWeb
|
BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication
GenomeWeb NEW YORK (GenomeWeb) – A study evaluating the combination of Bristol-Myers Squibb's immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) may support regulatory approval for the regimen as an option for lung cancer patients with a large number of … Phase 3 CheckMate-227 Trial Met Co-Primary Endpoint of PFS in NSCLC |
